biofest

Cell Genesys, Inc. Q1 2008 Earnings Call Transcript

Thanks for transcript. News seems very positive but I wish Steve would not raise money from institutions on very goods for the institutions without giving longterm shareholders the chance to participate. I am talking about the money raised at $4.22 including warrants to buy shares at $10.

Arena Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript

Looking good - especially at current share price near 52 week low.

Antigenics, Dendreon and Cell Genesys Find Hope in Overseas Treatment Approvals

Utter nonsense is a good discription of razormd's contribution. Where are the facts to support his position?

My INVESTools Saga Continues

Interesting debate but I was going to say waste of time.
However listening to Tom Sarnoff talking about 1987 crash was very amusing. Thank you Joe for directing me to such entertainment. By the way I disagree with Chungst I do not think the burden of proof lies with you. You raise questions which require answers rather than insults.

Curagen: A Biotech Bargain

Even bigger bargain now. Market value $51 million Cash and investments net of debt = $71 million.

What Gives With Avant Immunotherapeutics?

Take a look at Curogen. Deal worth $39 million. Market value $55 million Net cash after deal $72 million.

Antigenics, Dendreon and Cell Genesys Find Hope in Overseas Treatment Approvals

Excellent comment. The lack of flexibility of the FDA is remarkable. CYA is their motto.

Cell Genesys’ GVAX: A Multi-Trick Pony

I have been CEGE shareholder for many years and liked your article so I do not understand what KJN is complaining about. What is your take on the Takeda deal?

Onyx's New CEO - What You Won't Find In PR

No wonder he left NPSP

Which Has a Better Risk/Reward Ratio - Citigroup or Cell Genesys?

Excellent comparison - CITI vs CEGE. Who knows if FDA will approve GVAX but if they do $80 is not impossible. I remember CEGE over $50. Steve Sherwin is a bright guy working for the long haul. SPPI is also very interesting with multiple potential products and reasonable cash.